Edesa Biotech is a biopharmaceutical company focused on acquiring, developing and commercializing clinical-stage drugs for inflammatory and immune-related diseases. Co.'s primary product candidates include: EB05, which is a monoclonal antibody therapy for the treatment for Acute Respiratory Distress Syndrome in COVID-19 patients; and EB01, which is a secretory phospholipase 2 (sPLA2) inhibitor for the topical treatment for chronic allergic contact dermatitis, a potentially debilitating condition and occupational illness. Co.'s EB02 drug candidate represents a potential extension of its sPLA2 anti-inflammatory technology. Co.'s product candidate EB06, is a monoclonal antibody candidate. The EDSA YTD return is shown above.
The YTD Return on the EDSA YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether EDSA YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the EDSA YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|